284 related articles for article (PubMed ID: 22050607)
1. Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome.
Rinaldi B; Di Filippo C; Capuano A; Donniacuo M; Sodano L; Ferraraccio F; Rossi F; D'Amico M
Diabetes Obes Metab; 2012 Apr; 14(4):320-8. PubMed ID: 22050607
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.
Goyal SN; Bharti S; Bhatia J; Nag TC; Ray R; Arya DS
Diabetes Obes Metab; 2011 Jun; 13(6):533-41. PubMed ID: 21320264
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
[TBL] [Abstract][Full Text] [Related]
4. Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes.
Goyal S; Arora S; Bhatt TK; Das P; Sharma A; Kumari S; Arya DS
Chem Biol Interact; 2010 May; 185(3):271-80. PubMed ID: 20307515
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
Nakano A; Hattori Y; Aoki C; Jojima T; Kasai K
Hypertens Res; 2009 Sep; 32(9):765-9. PubMed ID: 19590508
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
[TBL] [Abstract][Full Text] [Related]
7. Effect of telmisartan on the expression of cardiac adiponectin and its receptor 1 in type 2 diabetic rats.
Guo Z; Zheng C; Qin Z; Wei P
J Pharm Pharmacol; 2011 Jan; 63(1):87-94. PubMed ID: 21155820
[TBL] [Abstract][Full Text] [Related]
8. Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats.
Kamari Y; Harari A; Shaish A; Peleg E; Sharabi Y; Harats D; Grossman E
Hypertens Res; 2008 Jan; 31(1):135-40. PubMed ID: 18360028
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
Tian Q; Miyazaki R; Ichiki T; Imayama I; Inanaga K; Ohtsubo H; Yano K; Takeda K; Sunagawa K
Hypertension; 2009 May; 53(5):798-804. PubMed ID: 19289654
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia.
Kasahara Y; Taguchi A; Uno H; Nakano A; Nakagomi T; Hirose H; Stern DM; Matsuyama T
Brain Res; 2010 Jun; 1340():70-80. PubMed ID: 20388500
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan ameliorates germ cell toxicity in the STZ-induced diabetic rat: studies on possible molecular mechanisms.
Kushwaha S; Jena GB
Mutat Res; 2013 Jul; 755(1):11-23. PubMed ID: 23648321
[TBL] [Abstract][Full Text] [Related]
12. Effect of telmisartan on VEGF-induced and VEGF-independent angiogenic responsiveness of coronary endothelial cells in normal and streptozotocin (STZ)-induced diabetic rats.
Chaudagar KK; Mehta AA
Clin Exp Hypertens; 2014; 36(8):557-66. PubMed ID: 24490705
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions.
Arozal W; Watanabe K; Veeraveedu PT; Ma M; Thandavarayan RA; Sukumaran V; Suzuki K; Kodama M; Aizawa Y
Toxicology; 2011 Jan; 279(1-3):91-9. PubMed ID: 20888384
[TBL] [Abstract][Full Text] [Related]
16. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway.
Sugimoto K; Kazdová L; Qi NR; Hyakukoku M; Kren V; Simáková M; Zídek V; Kurtz TW; Pravenec M
J Hypertens; 2008 Jun; 26(6):1209-15. PubMed ID: 18475159
[TBL] [Abstract][Full Text] [Related]
18. TLR4/MyD88/NF-κB signaling and PPAR-γ within the paraventricular nucleus are involved in the effects of telmisartan in hypertension.
Li HB; Li X; Huo CJ; Su Q; Guo J; Yuan ZY; Zhu GQ; Shi XL; Liu JJ; Kang YM
Toxicol Appl Pharmacol; 2016 Aug; 305():93-102. PubMed ID: 27292124
[TBL] [Abstract][Full Text] [Related]
19. Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Nagashima A; Watanabe R; Ogawa M; Suzuki J; Masumura M; Hishikari K; Shimizu T; Takayama K; Hirata Y; Nagai R; Isobe M
J Cardiovasc Pharmacol; 2012 Aug; 60(2):158-64. PubMed ID: 22561360
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]